comparemela.com

Latest Breaking News On - Colin kellaher - Page 4 : comparemela.com

Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study

By Colin Kellaher Lyra Therapeutics on Monday said a late-stage study of its lead drug candidate missed its main goal in a chronic inflammatory sinus disorder. Lyra said the Phase 3 study.

Colin-kellaher
Dow-jones
Markets

NextEra Energy Names New Chief Risk, Finance Officers

By Colin Kellaher NextEra Energy has named top finance executive Kirk Crews to the newly created post of executive vice president and chief risk officer. NextEra on Monday said Brian.

Colin-kellaher
Nextera-energy-partners
Nextera-energy
Goldman-sachs
Era-energy
Kirk-crews
Brian-bolster
Juno-beach
Dow-jones

Perficient Shares Surge Premarket on Deal to Go Private

By Colin Kellaher Shares of Perficient jumped nearly 55% in premarket trading Monday after the digital consultancy agreed to be acquired by Swedish private-equity firm EQT AB at an enterprise.

Sweden
Swedish
Colin-kellaher
Dow-jones
Markets

Pfizer Names Andrew Baum Chief Strategy, Innovation Officer

By Colin Kellaher Pfizer had hired Andrew Baum as the drugmaker s next chief strategy and innovation officer. Pfizer on Monday said Baum, who has been Citi s head of global healthcare and.

New-york
United-states
Albert-bourla
Aamir-malik
Colin-kellaher
Andrew-baum
Pfizer
Morgan-stanley
Dow-jones
Markets

FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal

By Colin Kellaher A $16.5 billion deal aimed at boosting Novo Nordisk s production of the weight-loss drug Wegovy is drawing extra scrutiny from U.S. antitrust regulators. Novo Holdings,.

Colin-kellaher
Exchange-commission-on
Capri-holdings
Novo-holdings
Novo-nordisk
Exchange-commission
Federal-trade-commission
Dow-jones

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.